Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

• Status: Completed
• Trial end date: 2020-10-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to observe the number of new cases of infections per population in a given time period and their characteristics in a pathology (myelodysplastic syndrome, MDS)that involves ineffective production (or dysplasia) of a class of blood cells.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antifungal Agents; Cephalosporins; Clotrimazole; Fluconazole; Itraconazole; Miconazole; Posaconazole; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

• All adult patients (>18 years) with newly diagnosed myelodysplastic syndrome or patients who have undergone a bone marrow reevaluation;

• Signed written informed consent;

Exclusion Criteria:

• Psychiatric patients;

• Patients with life expectancy less than three months.